AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa – GlobeNewswire (press release)
GlobeNewswire (press release) |
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
GlobeNewswire (press release) GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the … Applied Genetic Technologies (AGTC) Reports Dosing of 1st Patient in Phase 1/2 Clinical Study of Gene Therapy Applied Genetic Technologies Corporation (AGTC) Soars 7.14% on April 17 |
